About this Research Topic
SR-BI is an integral membrane glycoprotein that acts as a HDL-specific receptor and promotes the selective uptake of HDL cholesteryl esters into cells without degradation of lipoprotein structure. The interaction of HDL-like particles with the SR-B1 promotes the bi-directional cholesterol movement between cells and HDL and activates a signal transduction pathway and multiple subsequente kinase cascades and endothelial nitrous oxide synthase (eNOS).
Apart from the vital functions in cellular organisation and stability, cholesterol is thought to assume a preponderant role in the process of carcinogenesis and metastasis. The increased patterns of the SR-B1 receptor expression in several tumour cell lines and the plasmatic profiles of lipoproteins levels in cancer patients corroborate this hypothesis and unveil an new and exciting opportunity in cancer therapy and diagnosis. In this sense the SR-B1 receptor is thought to play a preponderant role in cancer cells by mediating the flow of cholesteryl esters into the cells.
This Frontiers Research Topic will focus on the specific aspects of this receptor-lipoprotein interaction and on how can we explore the selective SR-B1 mediated uptake of HDL’s core components, to deliver therapy directly to cancer cells.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.